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Birdshot chorioretinopathy in a male patient with
facioscapulohumeral muscular dystrophy
Evangelia Papavasileiou1 and Ann-Marie Lobo1,2*
Abstract
Background: We report a case of birdshot chorioretinopathy (BSCR) in a patient with facioscapulohumeral muscular
dystrophy (FSHD). A 40-year-old male with history of facioscapulohumeral muscular dystrophy with significant facial
diplegia and lagophthalmos presents for an evaluation of bilateral choroiditis with vasculitis and optic disc edema.
Clinical examination included fundus and autofluorescence photographs, fluorescein angiography, and optical
coherence tomography. To our knowledge, this patient represents the first reported case of birdshot chorioretinopathy
with facioscapulohumeral muscular dystrophy. Patients with FSHD can present with ocular findings and should be
screened with dilated fundus examinations for retinal vascular changes and posterior uveitis.
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Findings
A 40-year-old man with past medical history of faciosca-
pulohumeral muscular dystrophy (FSHD) diagnosed at
age 16 reports painless blurred vision in the left eye with
nyctalopia. He noticed bilateral worsening of his vision
over the past 1 year. Past ocular history was significant
for bilateral pterygia and dry eye syndrome.
On presentation, visual acuities were 20/30 in both eyes
(OU). Intraocular pressures were normal. External exam-
ination revealed significant facial diplegia and lagophthal-
mos. The slit-lamp examination showed bilateral nasal
and temporal pterygia. Fundus examination showed 2+
cells in the anterior vitreous and 1+ vitreous haze, vascu-
lar sheathing, few scattered pinpoint hemorrhages, and
multiple cream-colored circumscribed lesions, most not-
ably nasal to the disc OU (Figure 1a,b).
Visual field testing showed diffuse losses OU. There
was hypoautofluorescence with mottling surrounding
the peripapillary region and extending along the arcades
OU. (Figure 1c,d).
Fluorescein angiography was notable for diffuse retinal
perivascular and optic disc leakage (Figure 2a,b). OCT im-
aging revealed bilateral optic disc elevation (Figure 2e,f),
but no macular edema or subretinal fluid (Figure 2c,d).
Full-field electroretinogram testing was normal for the
right eye, with the exception of prolonged implicit time of
the b-wave maximal response, and abnormal for the left
eye, with reduced amplitudes of the isolated and maximal
rod responses and a significantly prolonged 30 Hz cone
flicker implicit time.
Serologic testing revealed + HLA A-29 and elevated
AST with normal ANA titer, Lyme Ab, CBC, ALT, RPR,
FTA-Abs, ACE, and lysozyme. Sixty milligrams of pred-
nisone daily was initiated with a slow taper. On follow-up
examination, there was improvement in the inflammation
with resolution of vitritis, stable optic disc edema, vascular
sheathing, and scattered hypopigmented choroidal lesions.
Systemic prednisone taper was continued and steroid-
sparing therapy with mycophenolate mofetil was initiated.
Discussion
FSHD is a rare, familial, autosomal dominant myopathy
(with a high percentage of sporadic cases) affecting 1 in
20,000 individuals and is characterized by progressive
muscle weakness with focal involvement of the facial,
shoulder, and upper arm muscles. There is a spectrum of
severity in FSHD that appears to be under the influence of
several factors. Females are less affected, as are earlier gen-
erations of affected family members [1]. Our patient had
genetic testing performed which revealed an FSHD dele-
tion mutation of allele 1 (allele size of 25 kb). A larger de-
letion results in an earlier and more severe disease onset.
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Extramuscular manifestations of FSHD include hearing
loss, retinal findings compatible with Coats disease, and
mental retardation [1,2]. Eye involvement includes ptosis,
lagophthalmos, abnormal electroretinogram findings in
70% with decreased amplitudes on flicker stimulation and
cone stimulation, and a reduction of the b-wave amplitude
in the scotopic electroretinogram (ERG) [3] and Coats-
like disease [4]. The term retinal telangiectasia has been
preferred to Coats disease because of the bilateral findings
in FSHD, compared with the unilateral involvement in
classic Coats disease [1].
Retinal vascular changes have been described in FSHD
and include minor abnormalities such as telangiectasia,
aneurysms, capillary nonperfusion, tortuosity of retinal
vessels and microaneurysms, and severe cases of intrar-
etinal and subretinal exudative retinopathy that mimics
Coats disease in less than 2% [1]. Fitzsimons et al. repor-
ted a case series of 75 patients and found that peripheral
retinal telangiectasia was found to be extremely common
in FSHD muscular dystrophy affecting 50% to 75% of the
patients. Of the 75 patients, only 4% showed posterior
pole abnormalities and 1% had related visual acuity loss
[1]. Massive exudative retinal detachment is a severe but
rare manifestation of retinal capillary leakage and tel-
angiectasia [1,5]. There have been reports that patients
with bilateral Coats-like disease changes may have an
underlying systemic or hereditary disease process, such
as FSHD, incontinentia pigmenti, CRB1-associated retinal
dystrophy, or familial exudative vitreoretinopathy [6]. Bi-
lateral Coats disease associated with severe FSHD has
been reported in an infant [6], three children [5], and an
adult female [7]. Most patients have asymptomatic retinal
telangiectasia found at ocular screening in adulthood after
diagnosis of FSHD.
Birdshot chorioretinopathy (BSCR) is a relatively rare
subtype of noninfectious posterior uveitis, which is strongly
correlated with the human leukocyte antigen (HLA)-A29
allele even though this is not required for the diagnosis.
In our case, the clinical picture was consistent with
BSCR and the positive HLA-A29 confirmed our clinical
diagnosis. Internationally accepted criteria for the diag-
nosis of BSCR are based on the presence of bilateral
Figure 1 Color fundus and autofluorescence. Color fundus wide-field photo of the right eye (a) and left eye (b) showed multiple cream-
colored circumscribed lesions with indistinct borders, most notably nasal to disc (arrows). Fundus autofluorescence photo of the right eye (c) and
left eye (d) showed RPE atrophy at the posterior pole affecting the macula area that did not correspond to the hypopigmented birdshot lesions.
The RPE atrophy as suggested by hypoautofluorescence was noted not only in the areas of hypopigmented lesions but also in the areas where
there appeared to be no hypopigmented lesions. The arrows show the borders of the abnormal autofluorescence at the posterior pole.
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mild intraocular inflammation, ‘birdshot lesions’, and the
absence of keratic precipitates and posterior synechiae
as seen in our patient [8].
BSCR is a slowly progressive disease with profound
dysfunction of vision. Blurring of vision and floaters are
the most prevalent presenting complaints [9]. Macular
edema occurs in up to 50% of patients with BSCR, and
it is the most common cause of visual loss [10]. Our pa-
tient complained of nyctalopia and blurred vision. Vitritis
and the retinal pigment epithelium (RPE) atrophy at the
macula area seen in autofluorescence give a possible
explanation for the impaired vision.
ERG abnormalities in patients with BSCR have been
well documented. Most common findings include a
reduced dim scotopic b-wave amplitude and delayed 30
Hz flicker implicit times in 70% of patients. The dim
scotopic b-wave amplitude presumably relates well with
night blindness and is a common finding in both BSCR
and FSHD [3,11]. Our patient had full-field electro-
retinogram testing which was abnormal for the left eye,
with a significantly prolonged 30 Hz cone flicker impli-
cit time.
This is the first report of BSCR in a patient with
muscular dystrophy. There was one reported case of a
woman who was diagnosed with congenital muscular
dystrophy, bilateral chorioretinitis, optic atrophy, and
retinal detachment [12]. There were choroidal atrophy
and RPE changes outside the macula area, in contrast
with our case where RPE atrophy involved the posterior
pole and the macula.
We hypothesize that there might be an underlying
immunological nexus between the perivascular inflam-
mation seen in the FSHD muscle and the retinal micro-
vascular abnormalities that also characterize BSCR [13].
T-cells have been implicated in the pathogenesis of
both diseases. Increased IL-17 levels have been demon-
strated in the aqueous humor of eyes with BSCR [14],
and increased serum IL-17, IL-23, and transforming
growth factor-beta 1 levels have also been found to be
elevated in some treatment-naïve patients with BSCR
[15]. In FSHD patients, it was found that inflammatory
infiltrates mainly composed by CD8 (+) T cells in mus-
cles and perivascular infiltrates mainly constituted by
CD4 (+) cells [16].
Figure 2 Fluorescein angiography and OCT image. (a,b) Fluorescein angiography photo of the right eye demonstrated staining and leakage
of fluorescein in the central and peripheral vessels, and staining of the optic nerve head. OCT image at the macula area of the right (c) and left
(d) eye showed no evidence of cystoid macular edema or subretinal fluid at the macula area. There are no changes in the macular architecture, such
as loss of the photoreceptor layer. OCT image at the optic nerve head area of the right (e) and left (f) eye showed elevation of the optic disc.
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The occurrence of BSCR in a patient with FSHD raises
the possibility of a common genetic etiology. BSCR is
strongly associated with human leukocyte antigen HLA-
A29, one of the 21 serologically defined variants of
HLA-A gene [9], and FSHD is an autosomal dominant
inherited myopathy that is associated in more than 95%
of cases with a low number of 3.3-kb tandem repeat
units, termed D4Z4, located on chromosome 4q35 [17].
In a recent genome-wide association study, ERAP2 hap-
lotype at chromosome 5q15 was associated with BSCR,
suggesting that other genes are involved in the disease
process [18]. A recently described transgenic mouse
model carrying the D4Z4 array of the FSHD allele devel-
oped progressive keratitis of unknown etiology resulting
in blindness, supporting the possibility of extramuscular
inflammation [19]. Further studies are needed to confirm
any overlap of genetic loci in these two rare diseases.
BSCR is considered to be an isolated ocular disorder
[20], despite a few reports in the literature describing its
possible association with systemic diseases including es-
sential hypertension, cerebrovascular accidents, hearing
loss, and cutaneous immune-mediated conditions such
as vitiligo and psoriasis [21]. This is the first report of
BSCR with FSHD.
Patients with FSHD can present with ocular findings
and should be screened with dilated fundus examina-
tions for retinal vascular changes and posterior uveitis.
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